Enhanced Group
Operates performance-enhancement-permitted sports events alongside telehealth protocols and wellness supplements.
Something off on this page? Send us feedback.
Profile
Combines a performance-enhancement-permitted sports property with U.S. telehealth and supplement sales, using the Games as an audience and brand engine for Live Enhanced. Intended revenue spans media, sponsorship, licensing and consumer wellness purchases, while clinical decisions and fulfillment sit with partners.
Runs the Enhanced Games, a performance-enhancement-permitted sports-entertainment property spanning live competition, media, sponsorships and licensed consumer products. It owns the event and brand intellectual property while partners handle production and content distribution; athlete stories and audience attention are intended to support sponsorship, media-rights, merchandise and licensing revenue.
Operates Live Enhanced, a U.S.-focused direct-to-consumer platform for clinician-guided prescription protocols and non-prescription supplements. It manages the customer-facing site, retail prices, marketing and non-clinical communication, while independent clinicians determine prescriptions and partner pharmacies fulfill approved care.
Relies on outside providers for clinical services, fulfillment, manufacturing, venues, production and distribution. Prescription protocols depend on state and federal rules governing medical practice, licensure, marketing, pharmacy fulfillment and data privacy. Its dual-class share structure gives Apeiron, executive chairman Christian Angermayer's investment group, decisive influence over director elections and major corporate actions.
Company facts
Key statistics
Year to date −84.2% · Average volume (30d) 923.6K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | −$0.18 | −$0.44 | −144.4% | $24.6M | $17.7M | −28.0% | −21.60% |
| Jun 3, 2026Q1 FY26 | −$0.14 | −$0.14 | 0.0% | $2.9K | $2.9K | 0.0% | −5.73% |
| May 4, 2026Q1 FY26 | −$0.14 | −$0.13 | +7.1% | $2.9K | $1.5K | −48.3% | −3.68% |
| Feb 9, 2026Q4 FY25 | — | $0.01 | — | — | $303.5K | — | — |
Financial highlights
| 4 quarters | — | — | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 | $2.8K | |
| Gross profit | — | — | $0 | $0 | $0 | $2.8K | |
| Operating income | — | — | −$2.3K | −$22.2K | −$104.4K | −$16.5M | |
| Net income | — | — | −$2.3K | $189.1K | $146.8K | −$16.4M | |
| Diluted EPS | — | — | $0.00 | $0.01 | $0.01 | −$0.13 | |
| Gross margin | — | — | — | — | — | 100.0% | |
| Operating margin | — | — | — | — | — | -600,410.5% |
Balance sheet, Mar 31, 2026Cash & short-term investments $54.6K · Total debt $0 · Total assets $26.2M · Shareholders' equity $25.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 128.66M · Float 64.85M · 50.4% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Davidson Kempner Capital Management LP | 1.29M | 1.00% | 13F | Aug 14, 2026 |
| LMR Partners LLP | 1.29M | 1.00% | 13F | Aug 14, 2026 |
| Anson Funds Management LP | 1.29M | 1.00% | 13F | Aug 13, 2026 |
| Citadel Advisors LLC | 1.29M | 1.00% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 1.05M | 0.82% | 13F | Aug 7, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Hims & Hers Health
Dominant DTC rival in hormones, weight loss and longevity.
- LifeMD
DTC protocol rival in TRT, hormone care and GLP-1 weight loss.
- TKO Group
Large live-sports rival for athletes, media rights and sponsors.
- WeightWatchers
Direct GLP-1 access rival in clinician-guided weight management.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Enhanced Group | $1.64 | +0.92% | $208.4M | — | — | 75,653.2 | — |
| Hims & Hers Health | $28.86 | +0.10% | $6.43B | — | 110.6 | 2.5 | +38.3% |
| LifeMD | $3.20 | +1.74% | $151.9M | — | — | 0.7 | −24.0% |
| TKO Group | $185.76 | +0.63% | $13.84B | 63.7 | 33.1 | 2.6 | +18.2% |
| WeightWatchers | $16.40 | +1.17% | $162.0M | — | — | 0.2 | — |
| Median | 63.7 | 71.8 | 1.6 | +18.2% |







